The speech and language disorder market is projected to expand from US$ 8.29 billion in 2022 to US$ 12.90 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.7% during this period.

Speech disorders refer to conditions where individuals struggle to produce specific speech sounds necessary for effective communication. In contrast, language disorders involve difficulties in understanding or conveying messages accurately. These disorders can sometimes be linked to behavioral or emotional issues. While various therapies are available in developed regions, a notable lack of healthcare professionals in underdeveloped or remote areas significantly hinders the growth of the speech and language disorder market.

The rise in the incidence of conditions that impact speech and language is a key driver for the growth of this market.

Diseases such as stroke and neurodegenerative disorders can impair the motor functions necessary for speech, leading to communication challenges. Parkinson's disease (PD), the second most prevalent neurodegenerative disorder after Alzheimer's, is particularly associated with cognitive decline and motor control issues. A report from the World Health Organization (WHO) in 2022 indicated that the prevalence of PD has doubled over the past 25 years, now affecting approximately 1% of the global population over 60. The Parkinson's Foundation reported that around 1 million individuals in the United States were living with PD in 2022, with projections suggesting this number will rise to 1.2 million by 2030. Globally, over 10 million people are affected by PD, with about 4% of cases diagnosed in individuals under 50. Common speech disorders linked to PD include dysarthria and aphasia, with the National Library of Medicine noting that around 90% of PD patients will experience dysarthria at some point during their illness.

According to the "Burden of Stroke in Europe" report by King's College London for the Stroke Alliance for Europe, the incidence of stroke in Spain is expected to reach 35%, with a prevalence of 31% by 2035. In the United States, stroke ranks as the fifth leading cause of death, occurring approximately every 40 seconds, with a stroke-related death every 4 minutes, as reported by IntechOpen. In China, a study published by Elsevier documented 17.8 million stroke cases, 3.4 million new strokes, and 2.3 million stroke-related fatalities in 2020. Consequently, the speech and language disorder market is likely to experience continued growth due to the rising prevalence of neurodegenerative diseases such as PD and stroke.

The speech and language disorder market report encompasses various regions, including North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). In 2022, North America held the largest share of the global market, driven by the increasing prevalence of neurodegenerative disorders, the growing use of application-based speech therapy, and the high incidence of speech disorders such as disfluency, along with the presence of major market players. The National Institute on Deafness and Other Communication Disorders reported that approximately 180,000 Americans are diagnosed with aphasia each year, with around 1 million currently living with the condition in the US.

The WHO, Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA) are among the primary and secondary sources consulted in the preparation of the speech and language disorder market report.